London (HRNW) AstraZeneca said its COVID-19 vaccine was 76% effective at preventing symptomatic illness in a new analysis of its major US trial – a tad lower than the level announced earlier this week in a report that was criticised for using outdated information.
US health officials had publicly rebuked the drugmaker for not using the most up-to-date information when it published an interim analysis on Monday that said the vaccine was 79% effective.
The latest data was based on 190 infections among more than 32,400 participants in the United States, Chile and Peru. The earlier interim data was based on 141 infections through Feb. 17.
“The primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults,” Mene Pangalos, executive vice president of BioPharmaceuticals R&D at AstraZeneca said in a statement.
Be the first to comment on "AstraZeneca COVID-19 vaccine 76% effective"